Background：Mirzotamab clezutoclax ABBV-155 is a first-in-class antibody drug conjugate comprised of a BCL-X L B-cell lymphoma - extra long inhibitor, solubilizing linker, and a monoclonal anti-B7H3 antibody. Methods: Patients pts with relapsed and/or refractory R/R solid tumors were administered mirzotamab clezutoclax with or without paclitaxel. Dose escalation of mirzotamab clezutoclax was guided by Bayesian continual reassessment.
